Aduro BioTech (NASDAQ:ADRO) received a $15.00 price objective from stock analysts at Oppenheimer in a report released on Monday, December 11th. The brokerage currently has a “buy” rating on the biotechnology company’s stock. Oppenheimer’s price objective would suggest a potential upside of 97.37% from the stock’s current price. Oppenheimer also issued estimates for Aduro BioTech’s Q1 2019 earnings at ($0.44) EPS, Q2 2019 earnings at ($0.47) EPS and Q3 2019 earnings at ($0.47) EPS.
A number of other brokerages have also commented on ADRO. BidaskClub lowered shares of Aduro BioTech from a “hold” rating to a “sell” rating in a research note on Saturday, December 9th. HC Wainwright reiterated a “buy” rating and issued a $18.00 price target on shares of Aduro BioTech in a research note on Wednesday, September 27th. Finally, William Blair reiterated an “outperform” rating on shares of Aduro BioTech in a research note on Monday, October 2nd. One analyst has rated the stock with a sell rating, one has given a hold rating and eight have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $17.71.
Aduro BioTech (NASDAQ ADRO) traded up $0.10 during trading on Monday, hitting $7.60. 628,416 shares of the stock traded hands, compared to its average volume of 488,200. The firm has a market cap of $579.78, a price-to-earnings ratio of -5.59 and a beta of 3.52. Aduro BioTech has a one year low of $6.01 and a one year high of $14.05.
Aduro BioTech (NASDAQ:ADRO) last released its quarterly earnings data on Tuesday, October 31st. The biotechnology company reported ($0.33) earnings per share for the quarter, missing the consensus estimate of ($0.30) by ($0.03). Aduro BioTech had a negative return on equity of 39.28% and a negative net margin of 548.92%. The firm had revenue of $3.79 million for the quarter, compared to analyst estimates of $4.04 million. During the same quarter in the prior year, the firm earned ($0.54) earnings per share. The firm’s revenue for the quarter was up .0% on a year-over-year basis. equities research analysts predict that Aduro BioTech will post -1.28 EPS for the current year.
In related news, EVP Dirk G. Brockstedt sold 65,223 shares of the stock in a transaction that occurred on Friday, December 15th. The shares were sold at an average price of $8.11, for a total value of $528,958.53. Following the completion of the transaction, the executive vice president now owns 137,826 shares of the company’s stock, valued at approximately $1,117,768.86. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, EVP Dirk G. Brockstedt sold 4,123 shares of the stock in a transaction that occurred on Monday, November 6th. The shares were sold at an average price of $8.04, for a total transaction of $33,148.92. Following the completion of the transaction, the executive vice president now directly owns 77,841 shares of the company’s stock, valued at approximately $625,841.64. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 239,765 shares of company stock valued at $2,036,057. 6.60% of the stock is currently owned by insiders.
Large investors have recently modified their holdings of the stock. JPMorgan Chase & Co. increased its position in Aduro BioTech by 283.7% in the 2nd quarter. JPMorgan Chase & Co. now owns 372,348 shares of the biotechnology company’s stock valued at $4,244,000 after acquiring an additional 275,295 shares during the period. Schwab Charles Investment Management Inc. increased its position in Aduro BioTech by 5.7% in the 1st quarter. Schwab Charles Investment Management Inc. now owns 145,112 shares of the biotechnology company’s stock valued at $1,560,000 after acquiring an additional 7,812 shares during the period. Vanguard Group Inc. increased its position in Aduro BioTech by 2.1% in the 1st quarter. Vanguard Group Inc. now owns 2,382,916 shares of the biotechnology company’s stock valued at $25,617,000 after acquiring an additional 48,840 shares during the period. PDT Partners LLC acquired a new position in Aduro BioTech in the 2nd quarter valued at approximately $570,000. Finally, Baillie Gifford & Co. increased its position in Aduro BioTech by 30.8% in the 3rd quarter. Baillie Gifford & Co. now owns 553,090 shares of the biotechnology company’s stock valued at $5,891,000 after acquiring an additional 130,390 shares during the period. 45.19% of the stock is owned by institutional investors and hedge funds.
Aduro BioTech Company Profile
Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.
Receive News & Ratings for Aduro BioTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro BioTech and related companies with MarketBeat.com's FREE daily email newsletter.